WHAT IS CLAIMED:

1. A compound of Formula (I):

 R^2 R^3 R^4 R^7 R^6 R^7 R^6 R^7 R^6

(I)

wherein:

 R^1 is selected from the group consisting of hydrogen, halo, alkyl, cyclkoalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, $-(CO)R^{15}$, $-NR^{13}R^{14}$, $-(CH_2)_rR^{16}$ and $-C(O)NR^8R^9$;

 $\rm R^2$ is selected from the group consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy, alkoxy, cyano, $\rm -NR^{13}R^{14}$, - $\rm NR^{13}C(O)\,R^{14}$, -C(O)R¹⁵, aryl, heteroaryl, and -S(O)₂NR¹³R¹⁴;

 R^3 is selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy, alkoxy, -(CO) R^{15} , -NR¹³R¹⁴, aryl, heteroaryl, -NR¹³S(O)₂R¹⁴, -S(O)₂NR¹³R¹⁴, -NR¹³C(O)R¹⁴,

 $-NR^{13}C\left(0\right)OR^{14}$ and $-SO_{2}R^{20}$ (wherein R^{20} is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl);

 $\rm R^4$ is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and $\rm -NR^{13}R^{14};$

 \mbox{R}^{5} is selected from the group consisting of hydrogen, alkyl and $-C\left(O\right) \mbox{R}^{10}\text{;}$

 \mbox{R}^{6} is selected from the group consisting of hydrogen, alkyl and $-C\left(O\right) \mbox{R}^{10}\text{;}$

 $\ensuremath{\mbox{R}^{7}}$ is selected from the group consisting of hydrogen,

209

20

25

5

25

30

35

5

10

alkyl, aryl, heteroaryl, $-C(0)R^{17}$ and $-C(0)R^{10}$; or

 R^6 and R^7 may combine to form a group selected from the group consisting of $-(CH_2)_4-$, $-(CH_2)_5-$ and $-(CH_2)_6-$; with the proviso that at least one of R^5 , R^6 or R^7 must be $-C(0)R^{10}$;

 ${\ensuremath{R}^8}$ and ${\ensuremath{R}^9}$ are independently selected from the group consisting of hydrogen, alkyl and aryl;

 R^{10} is selected from the group consisting of hydroxy, alkoxy, aryloxy, $-N(R^{11})(CH_2)_nR^{12}$, and $-NR^{13}R^{14}$;

 ${\ensuremath{\mathsf{R}}}^{11}$ is selected from the group consisting of hydrogen and alkyl;

 $\rm R^{12}$ is selected from the group consisting of $\rm -NR^{13}R^{14}$, hydroxy, $\rm -C(O)\,R^{15}$, aryl, heteroaryl, $\rm -N^+(O^-)\,R^{13}R^{14}$, $\rm -N\,(OH)\,R^{13}$, and $\rm -NHC\,(O)\,R^a$ (wherein $\rm R^a$ is unsubstituted alkyl, haloalkyl, or aralkyl);

 ${
m R}^{13}$ and ${
m R}^{14}$ are independently selected from the group consisting of hydrogen, alkyl, lower alkyl substituted with hydroxyalkylamino, cyanoalkyl, cycloalkyl, aryl and heteroaryl; or

 ${\bf R}^{13}$ and ${\bf R}^{14}$ may combine to form a heterocyclo group; ${\bf R}^{15}$ is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

 $\rm R^{16}$ is selected from the group consisting of hydroxy, -C(O)R¹⁵, -NR¹³R¹⁴ and -C(O)NR¹³R¹⁴;

 ${
m R}^{17}$ is selected from the group consisting of alkyl, cycloalkyl, aryl and heteroaryl;

R²⁰ is alkyl, aryl, aralkyl or heteroaryl; and n and r are independently 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.

2. The compound or salt of Claim 1 wherein:

 R^1 is selected from the group consisting of hydrogen, halo, alkyl, cyclkoalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, $-C(O)R^{15}$, $-NR^{13}R^{14}$, $-(CH_2)_rR^{16}$ and $-C(O)NR^8R^9$;

 ${
m R}^2$ is selected from the group consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy, alkoxy, $-{
m NR}^{13}{
m R}^{14}$, -

25

5

10

 $NR^{13}C(O)R^{14}$, $-C(O)R^{15}$, aryl, heteroaryl, and $-S(O)_2NR^{13}R^{14}$; R^3 is selected from the group consisting of hydrogen,

halogen, alkyl, trihalomethyl, hydroxy, alkoxy, $-(CO)R^{15}$, $-NR^{13}R^{14}$, aryl, heteroaryl, $-NR^{13}S(O)_2R^{14}$, $-S(O)_2NR^{13}R^{14}$, $-NR^{13}C(O)R^{14}$, and $-NR^{13}C(O)R^{14}$;

 \mbox{R}^4 is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and $-N\mbox{R}^{13}\mbox{R}^{14};$

 $\rm R^5$ is selected from the group consisting of hydrogen, alkyl and $\rm -C\left(O\right)R^{10};$

 R^6 is selected from the group consisting of hydrogen, alkyl and $-C(0)R^{10}$;

 R^7 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, $-C(0)R^{17}$ and $-C(0)R^{10}$;

 R^6 and R^7 may combine to form a group selected from the group consisting of $-(CH_2)_4-$, $-(CH_2)_5-$ and $-(CH_2)_6-$; with the proviso that at least one of R^5 , R^6 or R^7 must be $-C(0)R^{10}$;

 ${\ensuremath{R}^{8}}$ and ${\ensuremath{R}^{9}}$ are independently selected from the group consisting of hydrogen, alkyl and aryl;

 $\rm R^{10}$ is selected from the group consisting of hydroxy, alkoxy, aryloxy, $\rm -N\,(R^{11})\,(CH_2)_nR^{12}$ and $\rm -NR^{13}R^{14}$;

 ${\ensuremath{\mathsf{R}}}^{11}$ is selected from the group consisting of hydrogen and alkyl;

 R^{12} is selected from the group consisting of $-NR^{13}R^{14}$, hydroxy, $-C(0)R^{15}$, aryl and heteroaryl;

 ${\it R}^{13}$ and ${\it R}^{14}$ are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, aryl and heteroaryl;

 R^{13} and R^{14} may combine to form a group selected from the group consisting of $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_2O(CH_2)_2-$, and $-(CH_2)_2N(CH_3)(CH_2)_2-$;

 ${\ensuremath{\mathsf{R}}}^{15}$ is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

 $\rm R^{16}$ is selected from the group consisting of hydroxy, 35 $\rm -C(O)\,R^{15}$, $\rm -NR^{13}R^{14}$ and $\rm -C(O)\,NR^{13}R^{14}$;

 R^{17} is selected from the group consisting of alkyl,

cycloalkyl, aryl and heteroaryl; and n and r are independently 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.

- 5 3. The compound or salt of Claim 1 wherein R^5 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein: R¹¹ is hydrogen or lower unsubstituted alkvl; n is 2 or 3; and ${\ensuremath{\mathsf{R}}}^{12}$ is $-{\ensuremath{\mathsf{NR}}}^{13}{\ensuremath{\mathsf{R}}}^{14}$ wherein ${\ensuremath{\mathsf{R}}}^{13}$ and ${\ensuremath{\mathsf{R}}}^{14}$ are independently 10 unsubstituted lower alkyl.
 - 4. The compound or salt of Claim 1 wherein R^5 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein: R¹¹ is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and \mbox{R}^{12} is $-\mbox{NR}^{13}\mbox{R}^{14}$ wherein \mbox{R}^{13} and \mbox{R}^{14} combine to form a group selected from $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_2-O-(CH_2)_2-$ or -(CH₂)₂N(CH₃)(CH₂)₂-.
- 5. The compound of Claim 1 wherein R^5 is N-(2-dimethylamino-dimethylamethyl)aminocarbonyl, N-(2-diethylaminoethyl)-N-methylaminocarbonyl, N-(3-dimethylaminopropyl)aminocarbonyl, N-(2-diethylaminoethyl)aminocarbonyl, N-(3ethylaminopropyl) -aminocarbonyl, N-(2-25 ethylaminoethyl)aminocarbonyl, or N-(3diethylaminopropyl)aminocarbonyl.
 - 6. The compound of Claim 1 wherein R^5 is N-(2-diethylaminoethyl) aminocarbonyl or N-(2-ethylaminoethyl) aminocarbonyl.

30

35

7. The compound of Claim 1 wherein R^5 is 3-pyrrolidin-1ylpropylaminocarbonyl, 3-morpholin-4-ylpropylaminocarbonyl, 2-pyrrolidin-1-ylethylaminocarbonyl, 2morpholin-4-yl-ethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethyl-aminocarbonyl, 2-(3,5-dimethylpiperazin-15 8. The compound or salt of Claim 1 wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein:

10

in the second

1000

25

30

35

 ${\ensuremath{\mathsf{R}}}^{11}$ is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and

 ${\bf R}^{12}$ is $-{\bf NR}^{13}{\bf R}^{14}$ wherein ${\bf R}^{13}$ and ${\bf R}^{14}$ are independently unsubstituted lower alkyl.

9. The compound or salt of Claim 1 wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein:

 ${\ensuremath{\mathsf{R}}}^{11}$ is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and

 R^{12} is $-NR^{13}R^{14}$ wherein R^{13} and R^{14} combine to form a group selected from $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_2-O-(CH_2)_2-$ or $-(CH_2)_2N\,(CH_3)\,(CH_2)_2-$.

- 10. The compound or salt of Claim 1 wherein R⁶ is N-(2-dimethylamino-ethyl) aminocarbonyl, N-(2-diethyl-aminoethyl)-N-methylaminocarbonyl, N-(3-dimethylamino-propyl)-aminocarbonyl, N-(2-diethylaminoethyl)-aminocarbonyl, N-(2-ethylaminoethyl)-aminocarbonyl, N-(3-ethylaminopropyl)-aminocarbonyl, or N-(3-diethylaminopropyl) aminocarbonyl.
- 11. The compound or salt of Claim 1 wherein R^6 is N-(2-diethylaminoethyl) aminocarbonyl or N-(2-ethylaminoethyl) aminocarbonyl.
 - 12. The compound or salt of Claim 1 wherein R⁶ is 3-pyrrolidin-1-ylpropylaminocarbonyl, 3-morpholin-4-ylpropylamino-carbonyl, 2-pyrrolidin-1-ylethylamino-carbonyl, 2-morpholin-4-ylethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethyl-aminocarbonyl, 2-(3,5-

dimethylpiperazin-1-yl)ethyl-aminocarbonyl, 3-(4methylpiperazin-1-yl)propylamino-carbonyl or 3-(3,5dimethylpiperazin-1-yl)propylamino-carbonyl.

- The compound or salt of Claim 1 wherein R^5 is $-COR^{10}$ 5 13. wherein R^{10} is $-NR^{13}R^{14}$ wherein R^{13} is hydrogen and R^{14} is lower alkyl substituted with hydroxy, aryl, heteroalicyclic, heteroaryl, or carboxy.
- 10 14. The compound or salt of Claim 1 wherein R⁵ is 3-triazin-1ylpropylaminocarbonyl, 2-triazin-1-ylethylaminocarbonyl, 3-imidazol-1-ylpropylaminocarbony, pyridin-4-ylmethylaminocarbonyl, 2-pyridin-2-ylethylaminocarbonyl or 2-15 imidazol-1-yl ethylaminocarbonyl.
 - The compound or salt of Claim 1 wherein R^6 is $-COR^{10}$ 15. wherein R^{10} is $-NR^{13}R^{14}$ wherein R^{13} is hydrogen and R^{14} is lower alkyl substituted with hydroxy, aryl, heteroalicyclic, heteroaryl, or carboxy.
 - 16. The compound or salt of Claim 1 wherein R⁶ is 2-triazin-1ylpropylaminocarbonyl, 2-triazin-1-ylethylaminocarbonyl, 3-imidazol-1-ylpropylaminocarbony, pyridin-4-ylmethylaminocarbonyl, 2-pyridin-2-ylethylaminocarbonyl or 2imidazol-1-yl ethylaminocarbonyl.
 - 17. The compound or salt of Claim 1 wherein R^5 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein:

-5

25

30

 ${\ensuremath{\mathsf{R}}}^{11}$ is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and

- ${\rm R}^{12}$ is ${\rm -NR}^{13}{\rm R}^{14}$ wherein ${\rm R}^{13}$ and ${\rm R}^{14}$ together combine to form a heterocycle.
- 18. The compound or salt of Claim 1 wherein R^5 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein: 35 R¹¹ is hydrogen or lower unsubstituted alkyl;

n is 2 or 3; and

 R^{12} is $-NR^{13}R^{14}$ wherein R^{13} and R^{14} together combine to form a 5, 6 or 7 atom heterocycle containing a carbonyl group and one or two nitrogen atoms within the ring.

5

19. The compound or salt of Claim 1 wherein R⁵ is 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)ethylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propyl-aminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-aminocarbonyl, 3-(tetrahydropyrimidin-1-yl-2-one)propyl-aminocarbonyl, or 3-(2-oxopyrrolidin-1-yl)propyl-aminocarbonyl.

10

20. The compound or salt of Claim 1 wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein:

 ${\bf R}^{11}$ is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and

 \mbox{R}^{12} is $-\mbox{NR}^{13}\mbox{R}^{14}$ wherein \mbox{R}^{13} and \mbox{R}^{14} together combine to form a heterocycle.

21. The compound or salt of Claim 1 wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein:

 ${\ensuremath{\mathsf{R}}}^{11}$ is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and

 R^{12} is $-NR^{13}R^{14}$ wherein R^{13} and R^{14} together combine to form a 5, 6 or 7 atom heterocycle containing a carbonyl group and one or two nitrogen atoms within the ring.

30

35

25

22. The compound or salt of Claim 1 wherein R⁶ is 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)ethylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propyl-aminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-

25

30

35

5

10

 $S(O)_2NR^{13}R^{14}$ wherein R^{13} is hydrogen and R^{14} is hydrogen, aryl or alkyl; R^3 is selected from the group consisting of hydrogen, lower alkoxy, $-C(O)R^{15}$, $-NR^{13}C(O)R^{14}$, aryl optionally substituted with one or two substitutents selected from the group consisting of lower alkyl, halo, or lower alkoxy, and heteroaryl; and R^4 is hydrogen.

28. The compound or salt of Claim 23 wherein:

R¹ is hydrogen or phenyl;

R² is hydrogen, chloro, bromo, fluoro, methoxy, ethoxy, phenyl, cyano, dimethylaminosulfonyl, 3-chlorophenyl-aminosulfonyl, carboxy, methoxy, aminosulfonyl, methylaminosulfonyl, methylsulfonyl ethylsulfonyl, benzylsulfonyl, phenylaminosulfonyl, pyridin-3-yl-aminosulfonyl, dimethylaminosulfonyl, or isopropylamino-sulfonyl;

 R^3 is hydrogen, methoxy, carboxy, phenyl, pyridin-3-yl, 3,4-dichlorophenyl, 2-methoxy-5-isopropylphenyl, 4-n-butylphenyl, or 3-isopropylphenyl; and R^4 is hydrogen.

29. The compound or salt of Claim 23 wherein:

R1 is hydrogen;

R² is hydrogen, cyano, fluoro, chloro, or bromo;

 R^3 is hydrogen; and

R4 is hydrogen.

30. The compound or salt of Claim 25 wherein:

 R^1 is hydrogen, unsubstituted lower alkyl, - $C(0)\,NR^8R^9$, unsubstituted cycloalkyl or aryl;

 $\rm R^2$ is hydrogen, halo, lower alkoxy, cyano, aryl, - $\rm SO_2R20$, or -S(O) $_2\rm NR^{13}R^{14}$ wherein $\rm R^{13}$ is hydrogen and $\rm R^{14}$ is hydrogen, aryl or alkyl;

 $\rm R^3$ is selected from the group consisting of hydrogen, lower alkoxy, $-C(O)\,\rm R^{15}$, $-N\rm R^{13}C(O)\,\rm R^{14}$, aryl and heteroaryl;

and

5

10

25

30

35

R4 is hydrogen.

31. The compound or salt of Claim 25 wherein:

R¹ is hydrogen or phenyl;

R² is hydrogen, chloro, bromo, fluoro, methoxy, ethoxy, phenyl, dimethylaminosulfonyl, cyano, methylsulfonyl, ethylsulfonyl, benzylsulfonyl, 3-chlorophenyl-aminosulfonyl, carboxy, methoxy, aminosulfonyl, methylaminosulfonyl, phenylaminosulfonyl, pyridin-3-yl-aminosulfonyl, dimethylaminosulfonyl, or isopropylamino-sulfonyl;

R³ is hydrogen, methoxy, carboxy, phenyl, pyridin-3-yl, 3,4-dichlorophenyl, 2-methoxy-5-isopropylphenyl, 4-n-butylphenyl, 3-isopropylphenyl; and

 R^4 is hydrogen.

32. The compound or salt of Claim 25 wherein:

R¹ is hydrogen;

R² is hydrogen, cyano, fluoro, chloro, or bromo;

 R^3 is phenyl; and

R4 is hydrogen.

33. The compound or salt of Claim 1 wherein:

R¹ is hydrogen, unsubstituted lower alkyl, - C(O)NR⁸R⁹, unsubstituted cycloalkyl or aryl;

 $\rm R^2$ is hydrogen, halo, lower alkoxy, cyano, aryl or - $\rm S(O)_2NR^{13}R^{14}$ wherein $\rm R^{13}$ is hydrogen and $\rm R^{14}$ is hydrogen, aryl or alkyl; $\rm R^3$ is selected from the group consisting of hydrogen, lower alkoxy, -C(O)R^{15}, - NR^{13}C(O)R^{14}, aryl, and heteroaryl; and

 R^4 is hydrogen.

34. The compound or salt of Claim 1 wherein:

R¹ is hydrogen, or methyl;

R² is hydrogen, cyano, chloro, fluoro, or bromo;

 $\ensuremath{\mbox{R}^3}$ is selected from the group consisting of hydrogen or phenyl; and

R4 is hydrogen.

5 35. The compound or salt of Claim 33 or 34 wherein:

 R^5 is $-COR^{10}$;

 ${\ensuremath{\mathsf{R}}}^6$ is selected from the group consisting of hydrogen and unsubstituted lower alkyl; and

 R^7 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and $-C(0)R^{17}$ wherein R^{17} is hydroxy, unsubstituted lower alkyl or aryl.

36. The compound or salt of Claim 33 or 34 wherein:

 R^6 is $-COR^{10}$;

10

25

 $\mbox{\sc R}^5$ is selected from the group consisting of hydrogen and unsubstituted lower alkyl; and

 \mathbb{R}^7 is selected from the group consisting of hydrogen, alkyl, aryl, heteroaryl, and $-\mathbb{C}(0)\mathbb{R}^{17}$ wherein \mathbb{R}^{17} is hydroxy, unsubstituted lower alkyl or aryl.

- 37. The compound or salt of Claim 1 wherein R^5 is $-COR^{10}$ wherein R^{10} is $-NR^{13}R^{14}$ wherein R^{13} is hydrogen and R^{14} is lower alkyl substituted with hydroxy, lower alkyl substituted with hydroxyalkylamino, carboxy, or $-NR^{18}R^{19}$ wherein R^{18} and R^{19} are independently hydrogen or lower unsubstituted alkyl.
- 38. The compound or salt of Claim 1 wherein R⁵ is 2[(diethylamino)-2-hydroxyethyl]aminocarbonyl, 2-(N-ethylN-2-hydroxyethylamino)ethylaminocarbonyl,
 carboxymethylamino-carbonyl, or 2-hydroxyethylaminocarbonyl.
- 39. The compound or salt of Claim 1 wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{13}R^{14}$ wherein R^{13} is hydrogen and R^{14} is lower alkyl substituted with hydroxy, lower alkyl

5 40. The compound or salt of Claim 1 wherein R⁶ is [2- (diethylamino)-2-hydroxy]ethylaminocarbonyl, 2-(N-ethyl-N-2-hydroxyethylamino)ethylaminocarbonyl, carboxymethylaminocarbonyl, or 2-hydroxyethyl-aminocarbonyl.

10

- 41. The compound of Claim 1 wherein R^5 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein R^{12} is $-N^+(O^-)NR^{13}R^{14}$ or $-N^+(O^-)R^{13}$ wherein R^{13} and R^{14} are independently selected from the group consisting of unsubstituted lower alkyl.
- 42. The compound of Claim 1 wherein R^5 is 2-(N-hydroxy-N-ethylamino) ethylaminocarbonyl or $2-[N^+(O^-)(C_2H_5)_2]$ ethylaminocarbonyl
 - 43. The compound of Claim 1 wherein R^6 is $-COR^{10}$ wherein R^{10} is $-NR^{11}(CH_2)_nR^{12}$ wherein R^{12} is $-N^+(O^-)NR^{13}R^{14}$ or $-N^+(O^+)R^{13}$ wherein R^{13} and R^{14} are independently selected from the group consisting of unsubstituted lower alkyl.
- 25 44. The compound of Claim 1 wherein R^6 is 2-(N-hydroxy-N-ethylamino)ethylaminocarbonyl or 2-[N⁺(O⁻)(C₂H₅)₂]ethylaminocarbonyl.
- 45. The compound or salt of Claim 37, 38, 41 or 42 wherein:

 R⁶ is selected from the group consisting of hydrogen, or methyl; and

 R⁷ is selected from the group consisting of methyl,
 - R' is selected from the group consisting of methyl, hydrogen or phenyl.
- 35 46. The compound or salt of any of the Claims 39, 40, 43, 44 or 20-22 wherein:

 ${
m R}^{5}$ is selected from the group consisting of hydrogen, or methyl; and

 ${\ensuremath{\mathsf{R}}}^7$ is selected from the group consisting of methyl, hydrogen or phenyl.

5

47. The compound or salt of Claim 45 wherein:

R¹ is hydrogen;

R² is hydrogen, cyano, chloro, fluoro, or bromo;

 R^3 is hydrogen; and

R4 is hydrogen.

10

The compound or salt of Claim 46 wherein:

R¹ is hydrogen;

R² is cyano, chloro, fluoro, or bromo;

 R^3 is hydrogen; and

R4 is hydrogen.

The compound or salt of Claim 1, wherein the compound is selected from the group consisting of:

20

or an L-malate salt thereof.

- 50. A pharmaceutical composition, comprising a compound or salt of Claim 1 and, a pharmaceutically acceptable carrier or excipient.
- 5 51. A pharmaceutical composition, comprising a compound or salt of Claim 49 and, a pharmaceutically acceptable carrier or excipient.
- 52. A method for the modulation of the catalytic activity of a protein kinase comprising contacting said protein kinase with a compound or salt of Claim 1 or 49.
 - 53. The method of Claim 52 wherein said protein kinase is selected from the group consisting of a receptor tyrosine kinase, a non-receptor tyrosine kinase and a serine-threonine kinase.


30

35

- 54. A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound or salt of Claim 50 or Claim 51 and, a pharmaceutically acceptable carrier or excipient to said organism.
- 25 55. The method of Claim 54 wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.
 - 56. The method of Claim 54 wherein said protein kinase related disorder is selected from the group consisting of an EGFR related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.
 - 57. The method of Claim 54 wherein said protein kinase

related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

- The method of Claim m 54 wherein said protein kinase 58. related disorder is selected from the group consisting 10 of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.
 - The method of Claim 54 wherein said organism is a human. 59.
 - An intermediate of Formula (II): 60.



(II)

wherein: 25

5

 ${
m R}^{5}$ is selected from the group consisting of hydrogen, alkyl and $-C(0)R^{10}$;

 ${
m R}^6$ is selected from the group consisting of hydrogen, alkyl and $-C(0)R^{10}$;

R⁷ is selected from the group consisting of hydrogen, 30

10

alkyl, aryl, heteroaryl, $-C(O)R^{17}$ and $-C(O)R^{10}$; R^6 and R^7 may combine to form a group selected from the group consisting of $-(CH_2)_4-$, $-(CH_2)_5-$ and $-(CH_2)_6-$; with the proviso that at least one of R^5 , R^6 or R^7 must be

5 $-C(0)R^{10}$;

 R^{10} is selected from the group consisting of hydroxy, alkoxy, aryloxy, $-N(R^{11})(CH_2)_nR^{12}$ and $-NR^{13}R^{14}$;

 ${\ensuremath{\mathsf{R}}}^{\ensuremath{\mathsf{11}}}$ is selected from the group consisting of hydrogen and alkyl;

 R^{12} is selected from the group consisting of $-NR^{13}R^{14}$, hydroxy, $-C(0)R^{15}$, aryl and heteroaryl;

 ${
m R}^{13}$ and ${
m R}^{14}$ are independently selected from the group consisting of hydrogen, alkyl, cyanoalkyl, cycloalkyl, aryl and heteroaryl; or

 ${
m R}^{13}$ and ${
m R}^{14}$ may combine to form a heterocyclo group; ${
m R}^{15}$ is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy;

 ${
m R}^{17}$ is selected from the group consisting of alkyl, cycloalkyl, aryl and heteroaryl; and n is 1, 2, 3, or 4.